Back to Authors

Zhou, Li

https://orcid.org/0000-0003-3750-3309

Mayo Clinic

Incyte (United States)

Citations 4

Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
Forero‐Torres, Andres , Sher, Taimur , Scherle, Peggy , Schaub, Richard, Zhou, Li , Pulini, Jennifer, Leopold, Lance, Spear, Matthew A. , Phillips, Tycel , Diefenbach, Catherine , Talpaz, Moshe , Barr, Paul M.

Journal of Clinical Oncology | April 22, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8520-8520

10.1200/jco.2015.33.15_suppl.8520 Get It

A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Forero‐Torres, Andres , Sher, Taimur , Schaub, Richard, Zhou, Li , Pulini, Jennifer, Leopold, Lance, Spear, Matthew A. , Barr, Paul M. , Diefenbach, Catherine , Talpaz, Moshe , Phillips, Tycel

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8558-8558

10.1200/jco.2015.33.15_suppl.8558 Get It

A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Sher, Taimur , Lebovic, Daniel, Zhou, Li , Pulini, Jennifer, Spear, Matthew A. , Forero‐Torres, Andres , Barr, Paul M. , Phillips, Tycel

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS8607-TPS8607

10.1200/jco.2015.33.15_suppl.tps8607 Get It

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Forero‐Torres, Andres , Sher, Taimur , Diefenbach, Catherine , Johnston, Patrick B. , Talpaz, Moshe , Pulini, Jennifer, Zhou, Li , Scherle, Peggy , Chen, Xuejun , Phillips, Tycel , Barr, Paul M. , Talpaz, Moshe , Diefenbach, Catherine S

Blood | April 25, 2018 | Volume: 132 | Issue: 3 | Pages: 293-306

10.1182/blood-2017-10-812701 Get It

Key PointsINCB040093 was active across lymphoma subtypes, and the addition of itacitinib provided substantial activity in classic Hodgkin lymphoma. INCB040093 ± itacitinib had a manageable safety and tolerability profile; severe hepatic adverse effects were less common with the combination.